Goldenberg David M, Sharkey Robert M
Ther Deliv. 2011 Jun;2(6):675-9. doi: 10.4155/tde.11.44.
"Progress in the use of RAIT for cancer therapy has been slow but steady, involving the reengineerin1g of antibodies (reducing murine component, altering size and clearance properties), and pretargeting methods for improvving tumor:blood and tumor:organ ratios are continuing to evolve".
放射性免疫疗法（RAIT）在癌症治疗中的应用进展缓慢但稳步推进，涉及抗体的重新设计（减少鼠源成分、改变大小和清除特性），并且用于改善肿瘤与血液及肿瘤与器官比例的预靶向方法也在不断发展。
